Vernal keratoconjunctivitis is a globally widespread condition; however, it is majorly prevalent in hot and dry regions in Sub-Saharan Africa, Central and South America, the Mediterranean basin, Middle East regions and Asian regions.
The Vernal keratoconjunctivitis prevalence in the 7 Major Markets (the United States, EU5 (the United Kingdom, Spain, Germany, Italy, France) and Japan), China, Egypt, Saudi Arabia, and Russia was estimated to be 4,752,356 in 2017.
Among all the geographies, China accounted for the maximum Vernal keratoconjunctivitis prevalence with 2,248,706 cases. In 2017, in the US the Vernal keratoconjunctivitis prevalence was estimated to be 65,309.
The present Vernal keratoconjunctivitis market size in all the markets (the US, EU-5 (Germany, France, Italy, Spain, United Kingdom), Japan, China, MEA (Saudi Arabia, Egypt), and Russia) was estimated to be USD 307.89 million in 2017 and is anticipated to increase during the forecast period 2017-2030.
Some of the key pharma companies such as Allakos, iCo Therapeutics, Akari Therapeutics, and Santen, are proactively working to advance the Vernal keratoconjunctivitis market forward.
For more information on Vernal keratoconjunctivitis market, visit:
https://www.delveinsight.com/blog/vernal-keratoconjunctivitis-vkc-market/